A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Isatuximab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Islands
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 May 2017 Planned End Date changed from 1 Nov 2018 to 25 Jan 2019.
    • 17 May 2017 Planned primary completion date changed from 1 Mar 2018 to 23 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top